Roivant Sciences Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ROIV Nasdaq 2836 roivant.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Roivant Sciences Ltd.

Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue Estimates - Nov 5th, 2026 2:45 pm
Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value - Nov 4th, 2026 11:13 pm
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates - Nov 3rd, 2026 5:15 am
Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift - Oct 29th, 2026 7:00 am
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates - Oct 29th, 2026 5:35 am
Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials - Oct 23rd, 2026 11:25 am
Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results - Oct 21st, 2026 9:04 am
Roivant Sciences stock surges on positive uveitis trial data - Oct 21st, 2026 7:09 am
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 - Oct 21st, 2026 5:00 am
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 - Oct 21st, 2026 5:00 am
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) - Oct 21st, 2026 5:00 am
Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run - Oct 18th, 2026 6:20 pm
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class - Oct 8th, 2026 11:33 am
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months - Sep 28th, 2026 2:02 am
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging? - Sep 24th, 2026 11:02 am
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Sep 23rd, 2026 6:12 am
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - Sep 23rd, 2026 5:00 am
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test - Sep 22nd, 2026 4:27 am
What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data? - Sep 18th, 2026 5:15 am
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Sep 13th, 2026 3:45 am